Press Release
<< Back
Defactinib in Combination with Weekly Paclitaxel Achieves a Complete Response in Platinum-Resistant Ovarian Cancer
Interim results from an ongoing Phase 1/1b trial of VS-6063 (defactinib) in combination with weekly paclitaxel
At Verastem’s Research and Development Day on
“We have now confirmed the previously reported complete response by
RECIST criteria with a second radiographic scan at the end of cycle
four,” said Dr.
The Phase 1 dose escalation portion of the study in six patients treated
at the
In a randomized, placebo controlled study presented by McNeish et. al.
at the 2013
About Verastem, Inc.
Forward-looking statements:
This press release includes forward-looking statements about the
Company’s strategy, future plans and prospects, including statements
regarding the development of the Company’s compounds, including VS-6063,
and the Company’s FAK and diagnostic programs generally, the timeline
for clinical development and regulatory approval of the Company’s
compounds, expectations on patient enrollment in clinical studies, and
the structure of the Company’s planned clinical trials. The words
“anticipate,” “appear,” “believe,” “estimate,” “expect,” “intend,”
“may,” “plan,” “predict,” “project,” “target,” “potential,” “will,”
“would,” “could,” “should,” “continue,” and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Each
forward-looking statement is subject to risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied in such statement. Applicable risks and uncertainties include
the risks that the preclinical testing of the Company’s compounds and
preliminary data from clinical trials may not be predictive of the
results or success of later clinical trials, that the Company will be
unable to successfully complete the clinical development of its
compounds, including VS-6063, that the development of the Company’s
compounds will take longer or cost more than planned, and that the
Company’s compounds will not receive regulatory approval or become
commercially successful products. Other risks and uncertainties include
those identified under the heading “Risk Factors” in the Company’s
Annual Report on Form 10-K for the year ended
Source:
Verastem, Inc.
Brian Sullivan, 617-252-9314
bsullivan@verastem.com